These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39222512)

  • 1. In factor Xa inhibitor-related acute ICH, andexanet vs. usual care improved hemostatic efficacy but increased thrombotic events.
    Hunter BR; Kirschner JM
    Ann Intern Med; 2024 Sep; 177(9):JC101. PubMed ID: 39222512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.
    Huttner HB; Gerner ST; Kuramatsu JB; Connolly SJ; Beyer-Westendorf J; Demchuk AM; Middeldorp S; Zotova E; Altevers J; Andersohn F; Christoph MJ; Yue P; Stross L; Schwab S
    Stroke; 2022 Feb; 53(2):532-543. PubMed ID: 34645283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
    Connolly SJ; Sharma M; Cohen AT; Demchuk AM; Członkowska A; Lindgren AG; Molina CA; Bereczki D; Toni D; Seiffge DJ; Tanne D; Sandset EC; Tsivgoulis G; Christensen H; Beyer-Westendorf J; Coutinho JM; Crowther M; Verhamme P; Amarenco P; Roine RO; Mikulik R; Lemmens R; Veltkamp R; Middeldorp S; Robinson TG; Milling TJ; Tedim-Cruz V; Lang W; Himmelmann A; Ladenvall P; Knutsson M; Ekholm E; Law A; Taylor A; Karyakina T; Xu L; Tsiplova K; Poli S; Kallmünzer B; Gumbinger C; Shoamanesh A;
    N Engl J Med; 2024 May; 390(19):1745-1755. PubMed ID: 38749032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
    Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M
    Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - Individual patient data analysis of ANNEXA-4 and TICH-NOAC.
    Siepen BM; Polymeris A; Shoamanesh A; Connolly S; Steiner T; Poli S; Lemmens R; Goeldlin MB; Müller M; Branca M; Rauch J; Meinel T; Kaesmacher J; Z'Graggen W; Arnold M; Fischer U; Peters N; Engelter ST; Lyrer P; Seiffge D
    Int J Stroke; 2024 Jun; 19(5):506-514. PubMed ID: 38264861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.
    Demchuk AM; Yue P; Zotova E; Nakamya J; Xu L; Milling TJ; Ohara T; Goldstein JN; Middeldorp S; Verhamme P; Lopez-Sendon JL; Conley PB; Curnutte JT; Eikelboom JW; Crowther M; Connolly SJ;
    Stroke; 2021 Jun; 52(6):2096-2105. PubMed ID: 33966491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
    Connolly SJ; Crowther M; Eikelboom JW; Gibson CM; Curnutte JT; Lawrence JH; Yue P; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Demchuk AM; Pallin DJ; Concha M; Goodman S; Leeds J; Souza S; Siegal DM; Zotova E; Meeks B; Ahmad S; Nakamya J; Milling TJ;
    N Engl J Med; 2019 Apr; 380(14):1326-1335. PubMed ID: 30730782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
    Toyoda K; Arakawa S; Ezura M; Kobayashi R; Tanaka Y; Hasegawa S; Yamashiro S; Komatsu Y; Terasawa Y; Masuno T; Kobayashi H; Oikawa S; Yasaka M
    J Atheroscler Thromb; 2024 Mar; 31(3):201-213. PubMed ID: 37635060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Andexanet Alfa (Andexxa) Formulary Review.
    Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
    Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the Clinical Implications of Andexanet Alfa in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage.
    Chuck CC; Kim D; Kalagara R; Rex N; Madsen TE; Mahmoud L; Thompson BB; Jones RN; Furie KL; Reznik ME
    Neurology; 2021 Nov; 97(21):e2054-e2064. PubMed ID: 34556569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world utilization of andexanet alfa.
    Brown CS; Scott RA; Sridharan M; Rabinstein AA
    Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
    N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
    Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
    Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
    Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria.
    Dev P; Abousaab C; Zhou C; Sarode R
    J Thromb Thrombolysis; 2022 Feb; 53(2):249-256. PubMed ID: 34373984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding.
    Korobey MJ; Sadaka F; Javed M; Moynihan M; Alsaei A
    Neurocrit Care; 2021 Feb; 34(1):112-120. PubMed ID: 32430804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
    Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR
    J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
    Troyer C; Nguyen W; Xie A; Wimer D
    J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.